Insulet (NASDAQ:PODD) Upgraded by Wall Street Zen to “Strong-Buy” Rating

Wall Street Zen upgraded shares of Insulet (NASDAQ:PODD) from a buy rating to a strong-buy rating in a research note released on Saturday morning.

A number of other analysts have also weighed in on the stock. Barclays reduced their price objective on shares of Insulet from $286.00 to $198.00 and set an “underweight” rating for the company in a research note on Thursday, May 7th. Piper Sandler cut their price target on shares of Insulet from $360.00 to $210.00 in a report on Wednesday, May 6th. Weiss Ratings downgraded shares of Insulet from a “hold (c-)” rating to a “sell (d+)” rating in a research report on Wednesday, June 24th. JPMorgan Chase & Co. decreased their price objective on shares of Insulet from $340.00 to $275.00 and set an “overweight” rating for the company in a report on Thursday, May 7th. Finally, Stifel Nicolaus lowered their price objective on Insulet from $250.00 to $225.00 and set a “buy” rating on the stock in a research report on Friday, July 10th. Twenty-one equities research analysts have rated the stock with a Buy rating, five have assigned a Hold rating and two have assigned a Sell rating to the company’s stock. According to MarketBeat.com, Insulet currently has an average rating of “Moderate Buy” and a consensus target price of $233.38.

Insulet Stock Down 0.2%

PODD stock opened at $165.35 on Friday. The business has a 50 day moving average of $155.26 and a 200 day moving average of $198.24. The firm has a market cap of $11.45 billion, a PE ratio of 38.45, a price-to-earnings-growth ratio of 1.15 and a beta of 1.11. Insulet has a twelve month low of $138.79 and a twelve month high of $354.88. The company has a quick ratio of 1.81, a current ratio of 2.49 and a debt-to-equity ratio of 0.71.

Insulet (NASDAQ:PODD) last released its earnings results on Wednesday, May 6th. The medical instruments supplier reported $1.42 EPS for the quarter, topping the consensus estimate of $1.19 by $0.23. Insulet had a return on equity of 26.87% and a net margin of 10.44%.The business had revenue of $761.70 million for the quarter, compared to the consensus estimate of $729.89 million. During the same period in the previous year, the company posted $1.02 earnings per share. The company’s revenue for the quarter was up 33.9% compared to the same quarter last year. Insulet has set its FY 2026 guidance at 6.210- EPS. On average, research analysts forecast that Insulet will post 6.45 EPS for the current fiscal year.

Insider Transactions at Insulet

In related news, Director Timothy C. Stonesifer bought 2,790 shares of the stock in a transaction on Wednesday, June 3rd. The shares were acquired at an average price of $143.51 per share, for a total transaction of $400,392.90. Following the purchase, the director owned 9,041 shares of the company’s stock, valued at approximately $1,297,473.91. The trade was a 44.63% increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Corporate insiders own 0.36% of the company’s stock.

Institutional Inflows and Outflows

Several hedge funds have recently made changes to their positions in the stock. Larson Financial Group LLC boosted its holdings in Insulet by 114.6% in the fourth quarter. Larson Financial Group LLC now owns 88 shares of the medical instruments supplier’s stock worth $25,000 after purchasing an additional 47 shares during the last quarter. University of Texas Texas AM Investment Management Co. bought a new stake in Insulet in the 4th quarter worth approximately $26,000. DV Equities LLC purchased a new stake in Insulet during the 4th quarter valued at $28,000. Elyxium Wealth LLC purchased a new stake in Insulet during the 4th quarter valued at $28,000. Finally, Mcguire Capital Advisors Inc. purchased a new stake in Insulet during the 4th quarter valued at $29,000.

Key Stories Impacting Insulet

Here are the key news stories impacting Insulet this week:

• Positive Sentiment: UBS Group began research coverage of Insulet, potentially increasing institutional visibility and investor attention. However, the available report does not disclose UBS’s rating or price target. Insulet research coverage started at UBS Group
• Neutral Sentiment: The legal notices concern alleged violations of federal securities laws by Insulet and certain executives. The allegations have not been proven, and the financial impact of the litigation remains uncertain. Bronstein Gewirtz Grossman class action announcement
• Negative Sentiment: Several firms, including Bronstein Gewirtz & Grossman, Faruqi & Faruqi, Bleichmar Fonti & Auld, Schall Brown & Schwartz, DJS Law Group, Rosen Law Firm, and Glancy Prongay, publicized the pending class action. The notices generally cover investors who purchased Insulet securities between February 21 or May 21, 2025, and May 26, 2026, and allege investor losses related to disclosures involving defective Omnipod manufacturing controls. Bleichmar Fonti & Auld securities lawsuit notice
• Negative Sentiment: The concentration of similar legal announcements may amplify concerns about potential damages, management accountability, regulatory scrutiny, and reputational risk, even though no judgment or settlement has been reported. Insulet investor alert from Schall Brown & Schwartz

Insulet Company Profile

Insulet Corporation is a medical device company headquartered in Acton, Massachusetts, that develops, manufactures and sells insulin-delivery systems for people with diabetes. The company’s core business is the design and commercialization of its Omnipod family of tubeless, wearable insulin pumps and the consumable Pods that deliver insulin. Insulet’s products aim to simplify insulin delivery for people with type 1 diabetes and insulin-requiring type 2 diabetes by offering an alternative to traditional insulin pens and tethered pump systems.

The company’s product portfolio includes the Omnipod System line—disposable, waterproof Pods that adhere to the skin and deliver insulin—and the associated controllers and mobile applications used to program and monitor insulin delivery.